Beleaguered Arrowhead 'Cautiously Optimistic' About RNAi Deal, Closes Calando's Lab | GenomeWeb

By Doug Macron

This story has been updated to include details about Arrowhead's compliance with the Nasdaq's minimum stockholders' equity requirement.

Arrowhead Research's top official this week said that the firm's Calando Pharmaceuticals subsidiary continues to look for a partner for its RNAi drug-delivery system and clinical candidate, and that he is "cautiously optimistic" that pending phase I data on the drug will help drive a deal.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.